THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.5] ID: TIP-MED-000189

Calcium Carbonate (Typically Combined with Vitamin D3)

Active Ingredient / Scientific Identity: Calcium Carbonate • Class: Inorganic Calcium Salt (40% Elemental Calcium—Highest Elemental Yield; Requires Gastric Acid for Dissolution)

⚖️ Compare Profile
Generic / Entity NameCalcium Carbonate (Typically Combined with Vitamin D3) ([10.5])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassInorganic Calcium Salt (40% Elemental Calcium—Highest Elemental Yield; Requires Gastric Ac
Available Dosage FormsOral Film-Coated / Chewable Tablets: 1250 mg Calcium Carbonate = 500 mg Elemental Calcium (+ Vitamin D3 250 IU
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: In CKD Stages 3–5, Calcium Carbonate taken right with meals binds dietary phosphorus in the gut to treat hyperphosphat
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Calcium Carbonate (Typically Combined with Vitamin D3) (TIP-MED-000189, Reference Code [10.5]) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Inorganic Calcium Salt (40% Elemental Calcium—Highest Elemental Yield; Requires Gastric Acid for Dissolution). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.5], p. 129): Shelcal 500 / Shelcal-HD (Torrent), Cipcal 500 (Cipla), Ostocalcium (GSK), Gemcal (Alkem—with Calcitriol), Calcimax — Strengths & Dosage Forms: Oral Film-Coated / Chewable Tablets: 1250 mg Calcium Carbonate = 500 mg Elemental Calcium (+ Vitamin D3 250 IU, 500 IU, or 1000 IU); Paediatric/Adult Suspension: 250 mg elemental Ca/5 mL
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.5], p. 129): Shelcal 500 / Shelcal-HD (Torrent), Cipcal 500 (Cipla), Ostocalcium (GSK), Gemcal (Alkem—with Calcitriol), Calcimax — Strengths & Dosage Forms: Oral Film-Coated / Chewable Tablets: 1250 mg Calcium Carbonate = 500 mg Elemental Calcium (+ Vitamin D3 250 IU, 500 IU, or 1000 IU); Paediatric/Adult Suspension: 250 mg elemental Ca/5 mL
Dosage Forms & Available Strengths:
Oral Film-Coated / Chewable Tablets: 1250 mg Calcium Carbonate = 500 mg Elemental Calcium (+ Vitamin D3 250 IU, 500 IU, or 1000 IU); Paediatric/Adult Suspension: 250 mg elemental Ca/5 mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Inorganic Calcium Salt (40% Elemental Calcium—Highest Elemental Yield; Requires Gastric Acid for Dissolution) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Inorganic Calcium Salt (40% Elemental Calcium—Highest Elemental Yield; Requires Gastric Acid for Dissolution) for Prevention and treatment of calcium deficiency; adjunct to specific anti-osteoporotic therapy (bisphosphonates, denosumab, teriparatide) in postmenopausal and senile osteoporosis; glucocorticoid-induced osteoporosis prophylaxis (in patients on Prednisolone); pregnancy and lactation calcium supplementation; dietary phosphate binder in Chronic Kidney Disease (when taken WITH meals)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Prevention and treatment of calcium deficiency
  • adjunct to specific anti-osteoporotic therapy (bisphosphonates, denosumab, teriparatide) in postmenopausal and senile osteoporosis
  • glucocorticoid-induced osteoporosis prophylaxis (in patients on Prednisolone)
  • pregnancy and lactation calcium supplementation
  • dietary phosphate binder in Chronic Kidney Disease (when taken WITH meals)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 500 mg Elemental Calcium (1 tablet) once or twice daily (Total daily elemental calcium from diet + supplements should target 1000–1200 mg/day; never exceed 500–600 mg of elemental calcium in a single dose as intestinal saturable active transport [TRPV6] cannot absorb >500 mg at once!). Follow physician prescription.

Administration & Meal Timing: MUST be taken WITH or immediately AFTER a meal (typically Lunch)! (Calcium carbonate is water-insoluble and strictly requires gastric hydrochloric acid secreted during a meal to convert into soluble calcium chloride for absorption! Taking Calcium Carbonate on an empty stomach or while taking a PPI reduces absorption by >50%!). | After Lunch (01:30–02:30 PM)—scheduling Calcium after lunch automatically separates it by >6 hours from early-morning Levothyroxine, Bisphosphonates, and morning Iron/Antibiotics!

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: In CKD Stages 3–5, Calcium Carbonate taken right with meals binds dietary phosphorus in the gut to treat hyperphosphataemia; however, total elemental calcium intake must be restricted (<1500 mg/day) and monitored closely to prevent adynamic bone disease and coronary/aortic vascular calcification! Hepatic: Safe.
Elimination & Renal Adjustment:
Renal: In CKD Stages 3–5, Calcium Carbonate taken right with meals binds dietary phosphorus in the gut to treat hyperphosphataemia; however, total elemental calcium intake must be restricted (<1500 mg/day) and monitored closely to prevent adynamic bone disease and coronary/aortic vascular calcification! Hepatic: Safe.
Hepatic Impairment Considerations:
Renal: In CKD Stages 3–5, Calcium Carbonate taken right with meals binds dietary phosphorus in the gut to treat hyperphosphataemia; however, total elemental calcium intake must be restricted (<1500 mg/day) and monitored closely to prevent adynamic bone disease and coronary/aortic vascular calcification! Hepatic: Safe.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in hypercalcaemia (primary hyperparathyroidism, malignancy, sarcoidosis, Vitamin D toxicity), severe hypercalciuria, and active calcium renal stones. Caution in achlorhydria / chronic high-dose PPI users (prefer Calcium Citrate!).

Key Clinical Precautions: Renal: In CKD Stages 3–5, Calcium Carbonate taken right with meals binds dietary phosphorus in the gut to treat hyperphosphataemia; however, total elemental calcium intake must be restricted (<1500 mg/day) and monitored closely to prevent adynamic bone disease and coronary/aortic vascular calcification! Hepatic: Safe.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Constipation, abdominal bloating, and flatulence/belching (gastric acid reacts with carbonate to release CO2 gas in the stomach), chalky taste.
  • Hypercalcaemia, Milk-Alkali Syndrome (hypercalcaemia, metabolic alkalosis, and renal failure from excessive intake >3–4 g/day), nephrolithiasis (kidney stones—especially if taken on an empty stomach without food oxalate binding), vascular calcification in advanced CKD if calcium-phosphate product is elevated.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • MAJOR CHELATION INTERACTIONS (Enforce 2-to-4 Hour Separation!): • Levothyroxine (Thyronorm): Calcium carbonate adsorbs T4 in the gut—space by AT LEAST 4 HOURS! • Oral Iron (Ferrous salts): Calcium inhibits DMT-1 mucosal iron uptake—do not take Iron and Calcium in the same meal! • Fluoroquinolones (Ciprofloxacin, Levofloxacin) & Tetracyclines (Doxycycline): Forms insoluble chelates—space antibiotic 2 hours before or 4–6 hours after Calcium! • Oral Bisphosphonates (Alendronate): Completely blocks bisphosphonate absorption—space by ≥2–4 hours! • Proton Pump Inhibitors (Pantoprazole/Omeprazole): Suppress gastric acid and impair Calcium Carbonate dissolution
  • • Thiazide Diuretics: Increase risk of hypercalcaemia; Verapamil/CCBs: High calcium antagonises CCB effect; Digoxin: Hypercalcaemia precipitates digoxin arrhythmias

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: The 'Lunchtime Shelcal Rule': Instruct every patient: 'Always take your Calcium tablet right after Lunch—never in the early morning near your Thyroid or Acidity tablet, and never at the same meal as your Iron tablet!' Explain that taking it with lunch uses natural mealtime stomach acid to dissolve the tablet and binds dietary oxalates in the gut so kidney stones do not form.
  • Meal & Clock Timing Instruction: MUST be taken WITH or immediately AFTER a meal (typically Lunch)! (Calcium carbonate is water-insoluble and strictly requires gastric hydrochloric acid secreted during a meal to convert into soluble calcium chloride for absorption! Taking Calcium Carbonate on an empty stomach or while taking a PPI reduces absorption by >50%!). (After Lunch (01:30–02:30 PM)—scheduling Calcium after lunch automatically separates it by >6 hours from early-morning Levothyroxine, Bisphosphonates, and morning Iron/Antibiotics!)
  • Missed Dose Protocol: Take with the next meal (e.g., dinner, provided no interacting iron or antibiotic is taken at dinner); never take two 500 mg calcium tablets at the same time.
  • Geriatric Dispensing Pearl: In elderly CGHS patients who take daily Pantoprazole/Omeprazole (achlorhydria), suffer from chronic constipation, or have a history of kidney stones, Calcium Citrate Malate (CCM) is clinically superior to Calcium Carbonate.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated / Chewable Tablets: 1250 mg Calcium Carbonate = 500 mg Elemental Calcium (+ Vitamin D3 250 IU, 500 IU, or 1000 IU); Paediatric/Adult Suspension: 250 mg elemental Ca/5 mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.5] (p. 129)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.